(IHF) U.S. Healthcare Providers - Overview
Etf: Hospitals, Insurers, Pharmacy, Health-Services
Dividends
| Dividend Yield | 1.04% |
| Yield on Cost 5y | 1.09% |
| Yield CAGR 5y | -25.60% |
| Payout Consistency | 67.8% |
| Payout Ratio | - |
| Risk 5d forecast | |
|---|---|
| Volatility | 25.1% |
| Relative Tail Risk | -5.19% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.57 |
| Alpha | -22.74 |
| Character TTM | |
|---|---|
| Beta | 0.396 |
| Beta Downside | 0.371 |
| Drawdowns 3y | |
|---|---|
| Max DD | 29.85% |
| CAGR/Max DD | -0.14 |
Description: IHF U.S. Healthcare Providers January 26, 2026
The iShares U.S. Healthcare Providers ETF (IHF) tracks the SPDJI Healthcare Providers Index, allocating at least 80 % of its assets to the index’s constituent securities or economically equivalent holdings, with the remaining allocation permitted for futures, options, swaps, cash, or cash equivalents. Because it is classified as non-diversified, a single issuer can represent more than 25 % of the portfolio.
As of the most recent filing (Q4 2025):
• Expense ratio: 0.42 % (source: iShares fund factsheet).
• Assets under management (AUM): ≈ $5.2 billion, reflecting a modest inflow of 3 % year-to-date.
• Top holdings: UnitedHealth Group (~12 % of assets), CVS Health (~9 %), and Humana (~6 %), together accounting for roughly 27 % of the fund, underscoring its non-diversified nature.
Key sector drivers include the aging U.S. population-Medicare enrollment is projected to rise 2.5 % annually through 2030-and ongoing policy discussions around Medicare Advantage reimbursement, which can materially affect provider revenue streams.
For a deeper quantitative breakdown, you might explore ValueRay’s sector analytics to assess how these macro trends translate into expected fund performance.
What is the price of IHF shares?
Over the past week, the price has changed by -0.86%, over one month by -9.89%, over three months by -4.64% and over the past year by -12.52%.
Is IHF a buy, sell or hold?
What are the forecasts/targets for the IHF price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 44.8 | -0.6% |
IHF Fundamental Data Overview February 03, 2026
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 797.6m USD (797.6m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
EV/FCF = unknown (FCF TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 797.6m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 797.6m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 7.37% (E(797.6m)/V(797.6m) * Re(7.37%) + (debt-free company))
Discount Rate = 7.37% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Fair Price DCF = unknown (Cash Flow 0.0)